US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Spaulding Clinical Research Expands Clinical Pharmacology Facility With 12-Bed First-in-Human, High-Visibility Unit

February 19, 2013 – West Bend, Wisconsin, USA   Today, Spaulding Clinical Research, a change agent in the clinical research and medical device industries, announced that the company has completed a First-In-Human (FIH) study using their dedicated, 12-bed FIH High-Visibility-Unit (HVU).  The study was conducted for a biotech Sponsor developing a non-opioid analgesic. “Subject safety is our primary consideration in conducting any Clinical Pharmacology study.  As part of our commitment to safety, we designed the High-Visibility-Unit for First-in-Human studies or any study where the compound

Spaulding Clinical Research 2012 Study Metrics Lead Industry for Second Year in a Row

February 11, 2013 – West Bend, Wisconsin, USA   Today, Spaulding Clinical Research, a change agent in clinical research and medical device industries, announces that the company’s Clinical Pharmacology study metrics are the highest-quality reported by the industry for the second straight year.   “Last year we challenged the industry by publically reporting our study metrics that substantiate claims of high-quality study execution.  Not only did Spaulding Clinical make our metrics available to sponsors, but as a reminder we also placed them on the back of every Spaulding associate

Spaulding Clinical Research Reports Record Revenue for 2012

February 4, 2013 – West Bend, Wisconsin, USA   Today, Spaulding Clinical Research, a change agent in the clinical research and medical device industries, announces that the company tripled its fiscal yearly revenues for the period ending December 31st, 2012.  “Our customer retention and the ability to attract new Sponsors demonstrate Spaulding Clinical’s commitment to delivering the highest-quality, on-time study results for every study.  This is also reflected in our high net promoter score,” states Daniel Selness, General Manager and Sr. Vice President of Clinical Research at Spaulding.

Spaulding Clinical Growth Plan Results in $850,000 in Tax Credits through Wisconsin Economic Development Corporation

March 28, 2012 – West Bend, Wisconsin, USA   Governor Scott Walker visited Spaulding Clinical Research, LLC today to announce the company is eligible for up to $850,000 in tax credits through the Wisconsin Economic Development Corporation (WEDC) to facilitate the creation of 183 new full-time positions. “This investment by Spaulding reinforces Wisconsin as one of the leading states in the country in medical innovation,” said Governor Walker. “I am pleased to announce this support for Spaulding for the creation of quality jobs for Wisconsin workers.” In Governor Walker’s announcement,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media